Forsidebilde av showet OncoTalks | Oncology Insights at Your Fingertips

OncoTalks | Oncology Insights at Your Fingertips

Podkast av Ontada Learn

engelsk

Teknologi og vitenskap

Prøv gratis i 14 dager

99 kr / Måned etter prøveperioden.Avslutt når som helst.

  • 20 timer lydbøker i måneden
  • Eksklusive podkaster
  • Gratis podkaster
Prøv gratis

Om OncoTalks | Oncology Insights at Your Fingertips

OncoTalks is the podcast for community oncology providers and clinicians who want to stay on top of new treatments and the latest advancements in oncology. Join Ontada Learn and community oncologists from The US Oncology Network as they explore oncology with a focus on the latest breakthroughs in cancer care. Expect concise, impactful discussions with practical clinical insights tailored for the real-world community oncology setting. Additionally, don’t miss OncoTalks Case Journeys, where experts deep dive into oncology patient cases and treatment journeys. Join as they conduct comprehensive case reviews, explore key learnings, and discuss the latest research and advances related to each case. Tune into OncoTalks and start unlocking pathways to better patient care today!

Alle episoder

17 Episoder

Forsidebilde av episoden Provider Perspectives on BTKi Selection in CLL

Provider Perspectives on BTKi Selection in CLL

In this episode of OncoTalks, Dr. Yair Levy shares his approach to BTKi selection for patients with chronic lymphocytic leukemia (CLL), highlighting the growing role of second-generation BTK inhibitors, and the importance of tailoring treatment to individual patient characteristics. The discussion also explores the challenges providers face when navigating insurance requirements, medication access, and long-term adherence. Learn how thoughtful treatment selection and patient-centered education can help improve outcomes throughout the CLL treatment journey. Listen to Navigating the CLL Treatment Landscape: The Role of Physician Choice [https://oncotalks.podbean.com/e/navigating-the-cll-treatment-landscape-the-role-of-physician-choice/] as Dr. Levy discusses why preserving physician autonomy is essential to delivering optimal, patient-centered oncology care. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

I går - 12 min
Forsidebilde av episoden Navigating the CLL Treatment Landscape: The Role of Physician Choice

Navigating the CLL Treatment Landscape: The Role of Physician Choice

In this episode of OncoTalks, host Tulsi Patel is joined by Dr. Yair Levy to discuss the growing impact of utilization management policies on chronic lymphocytic leukemia (CLL) care. As treatment options expand, personalized therapy selection is more critical than ever, yet step therapy requirements and payer restrictions are increasingly shaping clinical decisions. Dr. Levy shares real-world insights on how these policies affect patient outcomes, treatment adherence, and provider workload. Tune in to explore why preserving physician autonomy is essential to delivering optimal, patient-centered oncology care. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

13. juli 2026 - 7 min
Forsidebilde av episoden Sacituzumab Govitecan: Advancing the Role of ADCs in Breast Cancer

Sacituzumab Govitecan: Advancing the Role of ADCs in Breast Cancer

In this episode of OncoTalks, host Tulsi Patel speaks with Dr. Hope Rugo about the evolving role of antibody‑drug conjugates (ADCs) in breast cancer, with a focus on sacituzumab govitecan, the first and currently only approved ADC for patients with previously treated metastatic triple‑negative breast cancer (mTNBC). Dr. Rugo highlights key clinical data supporting its approvals in mTNBC and HR‑positive/HER2‑negative disease, and discusses indications, efficacy, safety considerations, and emerging first‑line trial findings that may influence future treatment sequencing. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

20. mars 2026 - 12 min
Forsidebilde av episoden From Guidelines to Practice: Navigating Biomarker Testing in NSCLC

From Guidelines to Practice: Navigating Biomarker Testing in NSCLC

In this episode of OncoTalks, host Dr. Ira Zackon is joined by Dr. Alexander Spira to discuss comprehensive biomarker testing in non-small cell lung cancer (NSCLC). They unpack key findings from a recent study revealing variability in testing practices and emphasize the importance of comprehensive DNA- and RNA-based next-generation sequencing over single-gene testing. Tune in to review the latest clinical guidelines, learn how testing impacts treatment sequencing, and glean insights into how community oncology practices can overcome barriers to ensure that all NSCLC patients receive guideline-concordant testing and treatment.   Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

6. feb. 2026 - 7 min
Enkelt å finne frem nye favoritter og lett å navigere seg gjennom innholdet i appen
Enkelt å finne frem nye favoritter og lett å navigere seg gjennom innholdet i appen
Liker at det er både Podcaster (godt utvalg) og lydbøker i samme app, pluss at man kan holde Podcaster og lydbøker atskilt i biblioteket.
Bra app. Oversiktlig og ryddig. MYE bra innhold⭐️⭐️⭐️

Velg abonnementet ditt

Mest populær

Premium

20 timer lydbøker

  • Eksklusive podkaster

  • Ingen annonser i Podimo shows

  • Avslutt når som helst

Prøv gratis i 14 dager
Deretter 99 kr / måned

Prøv gratis

Premium Plus

100 timer lydbøker

  • Eksklusive podkaster

  • Ingen annonser i Podimo shows

  • Avslutt når som helst

Prøv gratis i 30 dager
Deretter 169 kr / måned

Prøv gratis

Bare på Podimo

Populære lydbøker

Ofte stilte spørsmål

Flere spørsmål og svar
Prøv gratis

Prøv gratis i 14 dager. 99 kr / Måned etter prøveperioden. Avslutt når som helst.